Match!
Jeffrey I. Weitz
McMaster University
ThrombinHeparinAnticoagulantBiochemistryMedicine
598Publications
90H-index
39.1kCitations
What is this?
Publications 610
Newest
#1Frits I. Mulder (UvA: University of Amsterdam)H-Index: 2
#2Nick van Es (UvA: University of Amsterdam)H-Index: 17
Last. Ajay K. Kakkar (UCL: University College London)H-Index: 61
view all 21 authors...
Source
#1Nigel Mackman (UNC: University of North Carolina at Chapel Hill)H-Index: 85
#2Wolfgang Bergmeier (UNC: University of North Carolina at Chapel Hill)H-Index: 47
Last. Jeffrey I. Weitz (McMaster University)H-Index: 90
view all 4 authors...
Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge is the side effect of bleeding. Improved understanding of the mechanisms of haemostasis and thrombosis has revealed new targets for attenuating thrombosis with the potential for less bleeding, including glycoprotein VI on platelets and factor XIa of the coagulation system. The efficacy and safety of new agents are curre...
Source
#1Frits I. Mulder (UvA: University of Amsterdam)H-Index: 2
#2Marcello Di NisioH-Index: 30
Last. Nick van Es (UvA: University of Amsterdam)H-Index: 17
view all 17 authors...
Introduction In cancer patients, current guidance suggests similar treatment for incidental and symptomatic venous thromboembolism (VTE), mainly based on retrospective data. We aimed to evaluate anticoagulant therapy in cancer patients with incidental and symptomatic VTE. Methods The Hokusai VTE Cancer study was a randomised controlled trial comparing edoxaban with dalteparin for cancer-associated VTE. The primary outcome was the composite of first recurrent VTE or major bleeding. Secondary outc...
1 CitationsSource
#1Jeffrey I. Weitz (McMaster University)H-Index: 90
#2Noel C. Chan (McMaster University)H-Index: 10
Source
#1Jeffrey I. Weitz (McMaster University)H-Index: 90
#2Gary E. Raskob (OU: University of Oklahoma)H-Index: 73
Last. Haitao Yang (Janssen Pharmaceutica)
view all 13 authors...
Patients with renal impairment are at higher risk of thrombosis and bleeding than those with normal renal function. The optimal rivaroxaban dose for thromboprophylaxis in acutely ill medical patients with renal impairment is unknown. MARINER and MAGELLAN were multicenter, randomized clinical trials of rivaroxaban in acutely ill medical patients. Efficacy and safety outcomes in patients with renal impairment in MARINER (7.5 mg once daily) were compared with those in patients with normal renal fun...
Source
#1Davide Capodanno (University of Catania)H-Index: 47
#2Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 122
Last. Dominick J. Angiolillo (UF: University of Florida)H-Index: 79
view all 19 authors...
Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks of ischaemia and bleeding remains substantial. Moreover, many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. Therefore, novel strategies are needed to prevent clinical events through mechanisms beyond platelet inhibition and with an acceptable associated risk of bleedin...
1 CitationsSource
#1Jeffrey I. Weitz (McMaster University)H-Index: 90
#2Rupert BauersachsH-Index: 27
Last. Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
view all 8 authors...
Importance The efficacy of factor XIa inhibition for thromboprophylaxis is unknown. Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa. Objective To compare different doses of osocimab with enoxaparin and apixaban for thromboprophylaxis in patients who have undergone knee arthroplasty. Design, Setting, and Participants Randomized, open-label, adjudicator-blinded, phase 2 noninferiority trial with observer blinding for osocimab doses, conducted at 54 hospitals in ...
2 CitationsSource
#1Frits I. Mulder (UvA: University of Amsterdam)H-Index: 2
#2Nick van Es (UvA: University of Amsterdam)H-Index: 17
Last. Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
view all 21 authors...
Abstract Background The safety and efficacy of edoxaban and dalteparin is unclear for several cancer groups. Methods We evaluated the occurrence of the primary outcome in large cancer groups. The primary outcome was the composite of recurrent VTE or major bleeding over 12 months. Results In patients with gastrointestinal cancer, the primary outcome occurred in 19.4% patients given edoxaban and in 15.0% given dalteparin (risk difference [RD], 4.4%; 95%-CI, −4.1% to 12.8%). The corresponding rates...
3 CitationsSource
#1Marc Schindewolf (University of Bern)H-Index: 1
#2Jeffrey I. Weitz (McMaster University)H-Index: 90
Traditionally, venous thromboembolism (VTE) resulting from major transient risk factors (e.g., surgery or trauma) or a major persistent risk factor such as cancer, has been defined as being provoked, whereas unprovoked VTE encompasses events without an identifiable cause. These categorizations influence anticoagulant treatment duration; unlike VTE provoked by major transient risk factors, extended anticoagulation beyond 3 months is advised for patients with cancer or unprovoked VTE due to risk p...
Source
#1Iqbal H. Jaffer (McMaster University)H-Index: 6
#2James C. Fredenburgh (McMaster University)H-Index: 25
Last. Jeffrey I. Weitz (McMaster University)H-Index: 90
view all 5 authors...
Abstract Background Patients with mechanical heart valves (MHVs) require warfarin to prevent thromboembolism. Dabigatran was less effective than warfarin in patients with MHVs, which prompted a black box warning against the use of direct oral anticoagulants for this indication. However, rivaroxaban and apixaban, which inhibit factor Xa, have not been evaluated in patients with MHVs. To determine whether rivaroxaban and apixaban would be effective, we used MHV-induced thrombin generation assays t...
Source
12345678910